Burning Rock Biotech (BNR) Common Equity (2019 - 2025)

Burning Rock Biotech's Common Equity history runs 7 years deep, the most recent figure standing at $75.5 million for Q4 2025.

• In Q4 2025, Common Equity fell 6.67% year-over-year to $75.5 million; the TTM figure through Dec 2025 stood at $75.5 million (down 6.67% YoY), while the FY2025 annual figure was $76.5 million, down 3.81% from the prior year.
• Common Equity was $75.5 million for Q4 2025 at Burning Rock Biotech, down from $80.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $288.6 million in Q4 2021 to a low of $75.5 million in Q4 2025.
• Historically, Common Equity has averaged $154.7 million across 5 years, with a median of $134.8 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Common Equity slumped 43.57% in 2022, then fell 6.67% in 2025.
• A 5-year view of Common Equity shows it stood at $288.6 million in 2021, then plunged by 43.57% to $162.9 million in 2022, then tumbled by 34.47% to $106.7 million in 2023, then fell by 24.23% to $80.9 million in 2024, then retreated by 6.67% to $75.5 million in 2025.
• The last three Common Equity figures came in at $75.5 million (Q4 2025), $80.9 million (Q4 2024), and $106.7 million (Q4 2023), per Business Quant data.